Research programme: p38 MAP kinase inhibitors - Astex Therapeutics

Drug Profile

Research programme: p38 MAP kinase inhibitors - Astex Therapeutics

Latest Information Update: 26 May 2010

Price : $50

At a glance

  • Originator Astex Therapeutics
  • Class Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammation; Rheumatoid arthritis

Most Recent Events

  • 31 May 2006 No development reported - Preclinical for Inflammation in United Kingdom (unspecified route)
  • 31 May 2006 No development reported - Preclinical for Rheumatoid arthritis in United Kingdom (unspecified route)
  • 20 Feb 2004 Astex's p38 MAP kinase inhibitors programme is available for partnering worldwide (http://www.astex-technology.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top